Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Colorectal Cancer
2.2 Symptoms
2.3 Epidemiology
2.4 Pathophysiology
2.4.1 Histology
2.4.2 Genetic Basis
2.4.3 Etiology of Colorectal Cancer
2.5 Diagnosis
2.5.1 Digital Rectal Examination
2.5.2 Fecal Occult Blood Test
2.5.3 Flexible Sigmoidoscopy
2.5.4 Colonoscopy
2.5.5 Virtual Colonoscopy
2.5.6 Double Contrast Barium Enema
2.6 Prognosis and Disease Staging
2.7 Treatment Options
2.7.1 Surgery and Radiation Therapy
2.7.2 Chemotherapy
2.7.3 Targeted Therapies
2.7.4 Resistance to Pharmacological Therapies
2.7.5 Treatment Guidelines
2.8 GBI Research Report Guidance
3 Marketed Products
3.1 Key Marketed Products
3.1.1 Immunotherapies
3.1.2 Targeted Therapies
3.1.3 Hyperthermic Intraperitoneal Chemotherapy
3.2 Heat Map for Marketed Products
4 Pipeline Analysis
4.1 Overall Pipeline
4.2 Pipeline Analysis by Molecule Type
4.3 Pipeline Analysis by Mechanism of Action
4.4 Clinical Trials
4.5 Failure Rate
4.6 Clinical Trial Size
4.7 Duration
4.8 Promising Drug Candidates in Pipeline
4.8.1 Lonsurf (TAS-102 (tipiracil + trifluridine)) – Taiho Pharmaceutical
4.8.2 Cyramza – ramucirumab – Eli Lilly and Company
4.8.3 TS-1/Teysuno (tegafur + gimeracil + oteracil) – Taiho Pharmaceutical
4.8.4 CPP-1X (eflornithine hydrochloride) + sulindac – Cancer Prevention Pharmaceuticals
4.8.5 MelCancerVac – DanDrit Biotech
4.8.6 Xilonix – XBiotech
4.8.7 Nintedanib – Boehringer Ingelheim
5 Market Forecast to 2020
5.1 Global Market
5.1.1 Treatment Use Patterns
5.1.2 Market Size
5.2 North America
5.2.1 Treatment Use Patterns
5.2.2 Annual Cost of Therapy
5.2.3 Market Size
5.3 Top Five European Markets
5.3.1 Treatment Use Patterns
5.3.2 Annual Cost of Therapy
5.3.3 Market Size
5.4 Japan
5.4.1 Treatment Use Patterns
5.4.2 Annual Cost of Therapy
5.4.3 Market Size
5.5 Drivers and Barriers for the Colorectal Cancer Therapeutics in Major Developed Markets to 2020
5.5.1 Drivers
5.5.2 Barriers
6 Deals and Strategic Consolidations
6.1 Licensing Agreements
6.1.1 Major Licensing Deals
6.2 Co-development Agreements
6.2.1 Major Co-development Agreements
7 Appendix
7.1 All Pipeline Drugs by Phase
7.1.1 Discovery
7.1.2 Preclinical
7.1.3 IND/CTA-Filed
7.1.4 Phase I
7.1.5 Phase II
7.1.6 Phase III
7.2 Market Forecasts to 2020
7.2.1 Global
7.2.2 US
7.2.3 Canada
7.2.4 UK
7.2.5 France
7.2.6 Germany
7.2.7 Italy
7.2.8 Spain
7.2.9 Japan
7.3 Market Definitions
7.4 Abbreviations
7.5 References
7.6 Research Methodology
7.6.1 Coverage
7.6.2 Secondary Research
7.6.3 Primary Research
7.6.4 Therapeutic Landscape
7.6.5 Geographical Landscape
7.6.6 Pipeline Analysis
7.7 Expert Panel Validation
7.8 Contact Us
7.9 Disclaimer